Want to see AGIO full AI Analyst Report?
AGIO Stock Chart & Stats
$36.36
$0.08(0.22%)
At close: 4:00 PM EDT
$36.36
$0.08(0.22%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume890.11K
Average Volume (3M)1.16M
Market Cap
$1.79B
Enterprise Value$1.62K
Total Cash (Recent Filing)$617.58M
Total Debt (Recent Filing)$31.17M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Oct 29, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.01
Shares Outstanding59,701,880
10 Day Avg. Volume1,012,320
30 Day Avg. Volume1,160,539
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$41.00Price Target Upside12.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.86
Revenue Forecast (FY)$174.87M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & High Gross MarginSustained high top-line growth paired with ~82% gross margins indicates the company’s products have strong unit economics and pricing power. Over 2–6 months this supports reinvestment in commercial scale-up and reduces dependency on immediate margin improvement to reach durable revenue expansion.
Robust Liquidity And Low LeverageA cash runway above $1B and minimal debt provide financial flexibility to fund clinical programs, commercial launches, and regulatory obligations without near-term refinancing. This materially lowers solvency risk and gives management time to execute pivotal catalysts over months.
Commercial Launch Execution And Regulatory PathwaySuccessful REMS-enabled launch momentum plus a planned accelerated sNDA signals both commercialization capability and a clear regulatory path to broaden indications. These structural steps can expand addressable patient populations and drive sustainable product revenue over the medium term.
Bears Say
Large Persistent Cash BurnConsistent multi-hundred-million operating and free cash outflows mean the company will rely on its cash reserve or external financing to sustain operations until profitable. Over 2–6 months this elevates dilution and budgeting risk, constraining discretionary R&D or commercial expansion if burn persists.
Concentration In U.S. Sales And Limited Ex-U.S. FootprintHeavy dependence on U.S. revenue exposes the company to single-market reimbursement dynamics and payer timing. Limited and volatile ex-U.S. sales reduce geographic diversification, slowing global uptake and leaving growth sensitive to U.S. access and policy implementation over coming quarters.
Development And Regulatory Uncertainty (tebapivat Exposure)A meaningful pharmacokinetic exposure shortfall and the need for confirmatory trials increase technical and regulatory risk, potentially requiring higher doses, additional studies, or delayed approvals. These issues can raise program costs and compress the timeline to commercial realization.
Agios Pharma News
AGIO FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Agios Pharmaceuticals lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is $1.79B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 81 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Jul 30, 2026. The company reported -$1.69 earnings per share for the quarter, missing the consensus estimate of -$1.655 by -$0.035.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.21.
How many shares outstanding does Agios Pharmaceuticals have?
Agios Pharmaceuticals has 59,701,880 shares outstanding.
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of -$1.69 in its last earnings report, missing expectations of -$1.655. Following the earnings report the stock price went down -6.455%.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.00 (12.76% Upside)
$41.00 (12.76% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 388.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.66%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong early commercial momentum and significant regulatory and pipeline progress—highlighted by 138% YoY revenue growth, a successful AQVESME U.S. launch with 242 prescriptions, planned sNDA submission for mitapivat in sickle cell disease, and a robust cash position (> $1B). Offsetting items included rising R&D and SG&A spend, limited ex‑U.S. revenue and quarter‑to‑quarter variability, a prescription‑to‑initiation lag as launch broadens, a 60% lower tebapivat exposure signal in low‑risk MDS necessitating higher‑dose evaluation, and some regulatory/competitive uncertainty that will need to be resolved by upcoming data and confirmatory trials. Overall, the positives (strong growth, launch execution, regulatory progress and ample liquidity) materially outweigh the near‑term challenges and risks.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$41.00
▲(12.76% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Iovance Biotherapeutics
―
Intellia Therapeutics
―
Beam Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
1.11% Insiders
26.25% Mutual Funds
6.15% Other Institutional Investors
45.78% Public Companies and
Individual Investors